Eunji Kim MS , Yu-Seon Jung PhD , Jongmin Lee PharmD, MS , Dal Ri Nam PharmD, MS , Seung-Hun You PhD , Ju Won Lee MS , Sook Ryun Park MD, PhD , Ji Seon Oh MD, PhD , Ye-Jee Kim PhD , Eun-Jung Jo MD, PhD , Nakyung Jeon PhD , Won-Jung Jung , Sun-Young Jung PhD
{"title":"基于韩国国民健康保险服务数据的免疫检查点抑制剂的实际使用模式。","authors":"Eunji Kim MS , Yu-Seon Jung PhD , Jongmin Lee PharmD, MS , Dal Ri Nam PharmD, MS , Seung-Hun You PhD , Ju Won Lee MS , Sook Ryun Park MD, PhD , Ji Seon Oh MD, PhD , Ye-Jee Kim PhD , Eun-Jung Jo MD, PhD , Nakyung Jeon PhD , Won-Jung Jung , Sun-Young Jung PhD","doi":"10.1016/j.clinthera.2025.07.014","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>This study was conducted to comprehensively understand the utilization patterns of immune checkpoint inhibitors (ICIs) in Korea, including their use in combination with traditional anticancer therapies.</div></div><div><h3>Methods</h3><div>We investigated the utilization of ICIs using claims data from Korea between 2017 and 2022. Patients with cancer were included in the study if they received at least one dose of ICIs, defined by drug codes in the claims data. We used descriptive statistics to identify patterns of ICIs use in combination with other anticancer therapies and ICIs use by year and cancer type.</div></div><div><h3>Findings</h3><div>During the study period, 41,208 patients received at least one dose of ICIs. Lung cancer (66.6%), urinary tract cancer (11.3%), and liver/biliary tract cancer (10.6%) were the most frequent cancer types. The prescription of ICIs particularly surged between 2020 and 2022 for liver/biliary tract cancer. Between 2017 and 2022, the use of ICIs increased from 1,155 to 15,034, with an increase every year. Since 2020, the use of ICIs in combination with other anticancer therapies and concurrent use of ICIs has increased sharply.</div></div><div><h3>Implications</h3><div>The number of patients utilizing ICIs in Korea has been steadily increasing. As regulatory approval of indications for ICIs has expanded, so has the range of indications for ICIs. In addition, the combination of ICIs with other anticancer therapies and the concurrent use of ICIs has increased in recent years, reflecting expanded treatment options for advanced cancers.</div></div>","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":"47 10","pages":"Pages 837-843"},"PeriodicalIF":3.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-World Utilization Patterns of Immune Checkpoint Inhibitors Based on the National Health Insurance Service Data in Korea\",\"authors\":\"Eunji Kim MS , Yu-Seon Jung PhD , Jongmin Lee PharmD, MS , Dal Ri Nam PharmD, MS , Seung-Hun You PhD , Ju Won Lee MS , Sook Ryun Park MD, PhD , Ji Seon Oh MD, PhD , Ye-Jee Kim PhD , Eun-Jung Jo MD, PhD , Nakyung Jeon PhD , Won-Jung Jung , Sun-Young Jung PhD\",\"doi\":\"10.1016/j.clinthera.2025.07.014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Purpose</h3><div>This study was conducted to comprehensively understand the utilization patterns of immune checkpoint inhibitors (ICIs) in Korea, including their use in combination with traditional anticancer therapies.</div></div><div><h3>Methods</h3><div>We investigated the utilization of ICIs using claims data from Korea between 2017 and 2022. Patients with cancer were included in the study if they received at least one dose of ICIs, defined by drug codes in the claims data. We used descriptive statistics to identify patterns of ICIs use in combination with other anticancer therapies and ICIs use by year and cancer type.</div></div><div><h3>Findings</h3><div>During the study period, 41,208 patients received at least one dose of ICIs. Lung cancer (66.6%), urinary tract cancer (11.3%), and liver/biliary tract cancer (10.6%) were the most frequent cancer types. The prescription of ICIs particularly surged between 2020 and 2022 for liver/biliary tract cancer. Between 2017 and 2022, the use of ICIs increased from 1,155 to 15,034, with an increase every year. Since 2020, the use of ICIs in combination with other anticancer therapies and concurrent use of ICIs has increased sharply.</div></div><div><h3>Implications</h3><div>The number of patients utilizing ICIs in Korea has been steadily increasing. As regulatory approval of indications for ICIs has expanded, so has the range of indications for ICIs. In addition, the combination of ICIs with other anticancer therapies and the concurrent use of ICIs has increased in recent years, reflecting expanded treatment options for advanced cancers.</div></div>\",\"PeriodicalId\":10699,\"journal\":{\"name\":\"Clinical therapeutics\",\"volume\":\"47 10\",\"pages\":\"Pages 837-843\"},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0149291825002528\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0149291825002528","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Real-World Utilization Patterns of Immune Checkpoint Inhibitors Based on the National Health Insurance Service Data in Korea
Purpose
This study was conducted to comprehensively understand the utilization patterns of immune checkpoint inhibitors (ICIs) in Korea, including their use in combination with traditional anticancer therapies.
Methods
We investigated the utilization of ICIs using claims data from Korea between 2017 and 2022. Patients with cancer were included in the study if they received at least one dose of ICIs, defined by drug codes in the claims data. We used descriptive statistics to identify patterns of ICIs use in combination with other anticancer therapies and ICIs use by year and cancer type.
Findings
During the study period, 41,208 patients received at least one dose of ICIs. Lung cancer (66.6%), urinary tract cancer (11.3%), and liver/biliary tract cancer (10.6%) were the most frequent cancer types. The prescription of ICIs particularly surged between 2020 and 2022 for liver/biliary tract cancer. Between 2017 and 2022, the use of ICIs increased from 1,155 to 15,034, with an increase every year. Since 2020, the use of ICIs in combination with other anticancer therapies and concurrent use of ICIs has increased sharply.
Implications
The number of patients utilizing ICIs in Korea has been steadily increasing. As regulatory approval of indications for ICIs has expanded, so has the range of indications for ICIs. In addition, the combination of ICIs with other anticancer therapies and the concurrent use of ICIs has increased in recent years, reflecting expanded treatment options for advanced cancers.
期刊介绍:
Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.